IGC

IGC Pharma, Inc. IGC

NYSESmall CapHealthcare

13F Pro quality score

Rank #2,809 of 2,925

Why it scores 16Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$265.0K

Quarter to Jun 30

Net income

$-2.94M

Quarter to Jun 30

Free cash flow

$-1.35M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.41M total
GEODE CAPITAL MANAGEMENT, LLC
$239.2K-15.7%
VANGUARD CAPITAL MANAGEMENT LLC
$221.7K+13.4%
BlackRock, Inc.
$191.4K0.0%
AdvisorShares Investments LLC
$184.5KNew
CITADEL ADVISORS LLC
$119.0KNew
VANGUARD FIDUCIARY TRUST CO
$114.1K+0.8%
RENAISSANCE TECHNOLOGIES LLC
$78.0K-40.8%
STATE STREET CORP
$54.6K0.0%
NORTHERN TRUST CORP
$46.3K+50.1%
LAWOOD & CO
$20.4K0.0%
GOLDMAN SACHS GROUP INC
$17.8K0.0%
JANE STREET GROUP, LLC
$17.0KNew
DEARBORN PARTNERS LLC
$15.6K0.0%
TRUIST FINANCIAL CORP
$13.2K+32.7%
CITIGROUP INC
$12.5KNew
Fisher Asset Management, LLC
$11.8K0.0%
XTX Topco Ltd
$10.7K-22.3%
MORGAN STANLEY
$9.6K+0.2%
COMMONWEALTH EQUITY SERVICES, LLC
$9.1K-1.5%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$7.9K-76.4%
Tower Research Capital LLC (TRC)
$7.5K+31.2%
Vanguard Global Advisers, LLC
$4.1K0.0%
Wealthcare Advisory Partners LLC
$2.7K0.0%
Burnham & Co LLC
$1.4K--
Geneos Wealth Management Inc.
$8100.0%
See all 36 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

Free Cash Flow

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IGC

Earnings Per Share

13fpro.ai/company/IGC

Loading ratio trend…

IGC key financials by period

Reported revenue, net income and operating margin by fiscal year, from IGC Pharma, Inc.'s annual filings on SEC EDGAR.

IGC Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.3M$-7.1M—
FY 2024$1.3M$-13.0M—
FY 2023$911.0K$-11.5M—
FY 2022$397.0K$-15.0M—
FY 2021$898.0K$-8.8M—
FY 2020$4.1M$-7.3M-168.6%
Source: IGC filings on SEC EDGAR →

IGC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About IGC Pharma, Inc. (IGC): stock profile, AI score and financials

IGC Pharma, Inc. (IGC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IGC at 15.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,809 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2027), IGC Pharma, Inc. reports quarterly revenue of $265.0K, net income of $-2.9M, free cash flow of $-1.4M. Top institutional holders of IGC by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. IGC trades on the NYSE exchange and files with the SEC under CIK 1326205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IGC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IGC Pharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1326205 →